Progress and perspectives of antibody-drug conjugates in cancer treatment

Minglu Xu

doi:10.1117/12.2669936

24 March 2023 Progress and perspectives of antibody-drug conjugates in cancer treatment

Minglu Xu

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 1261169 (2023) https://doi.org/10.1117/12.2669936
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

At a time of high prevalence of cancer and painful chemotherapy, the effective and patient-friendly cancer therapy is necessary. The use of antibody-drug conjugates (ADCs) to develop anti-cancer drugs has become a hotspot. ADCs typically consist of a monoclonal antibody (mAb) linked to a cytotoxic payload via a linker. It can not only target cancer cells specifically and precisely, but also kill and eliminate cancer cells efficiently. Although there are now three generations of ADC drugs active in the treatment of cancer, and some drugs have been approved by the FDA, there are still some limitations. Whether prevalent adverse reactions or drug resistance will affect the safety and efficacy of ADC drugs. To investigate the optimal efficacy of ADC after optimization, researches are constantly being promoted. Both the improvement of ADC structure and combination therapy can be beneficial to obtain more treatable ADC drugs. Therefore, this review discussed how ADCs attacked cancer cells from the mechanism of the different ways in which ADCs work in order to gain a deeper understanding of how ADCs are effective in treating cancer. At the same time, for the purpose of obtaining better drugs, on the basis of briefly introducing the development history of ADCs and summarizing the three generations of ADCs, the drug resistance of ADCs was analyzed and the future improvement was prospected.

Citation Download Citation

Minglu Xu "Progress and perspectives of antibody-drug conjugates in cancer treatment", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 1261169 (24 March 2023); https://doi.org/10.1117/12.2669936

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available